切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2023, Vol. 17 ›› Issue (03) : 250 -254. doi: 10.3877/cma.j.issn.1674-3946.2023.03.004

所属专题: 总编推荐 指南共识

专家论坛

初诊Ⅳ期乳腺癌诊疗临床实践指南解读
王嘉1, 郭宝良2, 王杉1, 张殿龙3, 王弥迦1, 周天阳1, 张建国2,(), 金锋4,()   
  1. 1. 116000 辽宁大连,大连医科大学附属第二医院乳腺外科
    2. 150086 哈尔滨,哈尔滨医科大学附属第二医院乳腺外科
    3. 116000 辽宁大连,大连大学附属中山医院乳腺外科
    4. 110001 沈阳,中国医科大学附属第一医院乳腺外科
  • 收稿日期:2023-01-29 出版日期:2023-06-26
  • 通信作者: 张建国, 金锋

Interpretation of clinical practice guidelines for diagnosis and treatment of de novo stage Ⅳ breast cancer

Jia Wang1, Baoliang Guo2, Shan Wang1, Dianlong Zhang3, Mijia Wang1, Tianyang Zhou1, Jianguo Zhang2,(), Feng Jin4,()   

  1. 1. Department of Breast Surgery,The Second Hospital of Dalian Medical University,Dalian Liaoning Province 116000,China
    2. Department of Breast Surgery,The Second Affiliated Hospital of Harbin Medical University,Harbin Heilongjiang Province 150086,China
    3. Department of Thyroid and Breast Surgery,The Affiliated Zhongshan Hospital of Dalian University,Dalian Liaoning Province 116000,China
    4. Department of Breast Surgery,The First Affiliated Hospital of China Medical University,Shenyang Liaoning Province 110001,China
  • Received:2023-01-29 Published:2023-06-26
  • Corresponding author: Jianguo Zhang, Feng Jin
  • Supported by:
    Youth Project of National Natural Science Foundation(81602309); Key project of Liaoning Provincial Department of Science and Technology(20180530075)
引用本文:

王嘉, 郭宝良, 王杉, 张殿龙, 王弥迦, 周天阳, 张建国, 金锋. 初诊Ⅳ期乳腺癌诊疗临床实践指南解读[J]. 中华普外科手术学杂志(电子版), 2023, 17(03): 250-254.

Jia Wang, Baoliang Guo, Shan Wang, Dianlong Zhang, Mijia Wang, Tianyang Zhou, Jianguo Zhang, Feng Jin. Interpretation of clinical practice guidelines for diagnosis and treatment of de novo stage Ⅳ breast cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 250-254.

初诊Ⅳ期乳腺癌的首选治疗为依据分子分型制定的全身系统治疗,得益于乳腺癌新型药物的快速更新迭代和基因检测工具临床应用的普及,初诊Ⅳ期乳腺癌患者生存时间和生活质量得到大幅度改善,有关局部外科处理原则成为临床关注的热点问题。基于此,中华医学会外科学分会乳腺外科学组牵头,对初诊Ⅳ期乳腺癌诊疗过程的关键问题展开讨论并共同制定了《初诊Ⅳ乳腺癌诊疗临床实践指南(2022版)》。

The first choice of treatment for de novo stage Ⅳ breast cancer is systemic therapy based on molecular typing. Thanks to the rapid iteration of new anti-cancer drugs and the popularization of clinical application of genetic testing tools,the survival time and quality of life of patients with de novo stage Ⅳ breast cancer have been greatly improved,and the principles of local surgical treatment have become a hot issue of clinical concern. Based on this,the Chinese Society of Breast Surgery took the lead and conducted a discussion on the key issues in the diagnosis and treatment of de novo stage Ⅳ breast cancer,developed the clinical practice guidelines for diagnosis and treatment of de novo stage Ⅳ breast cancer(2022 edtition).

[1]
Siegel RLMiller KDFuchs HE,et al. Cancer Statistics,2021[J]. CA Cancer J Clin202171(1):7-33.
[2]
Zheng AGuo BLZhang JG,et al. Clinical information and management status of de novo stage Ⅳ breast cancer patients:a Chinese multicenter investigation(CSBrS-002)[J]. Chin Med J(Engl)2021134(13):1569-1575.
[3]
Malmgren JAMayer MAtwood MK,et al. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time:1990-2010[J]. Breast Cancer Res Treat2018167(2):579-590.
[4]
Giuliano AEEdge SBHortobagyi GN. Eighth Edition of the AJCC Cancer Staging Manual:Breast Cancer[J]. Ann Surg Oncol201825(7):1783-1785.
[5]
国家肿瘤质控中心乳腺癌专家委员会,中国抗癌协会乳腺癌专业委员会,中国抗癌协会肿瘤药物临床研究专业委员会. 中国晚期乳腺癌规范诊疗指南(2020版)[J]. 中华肿瘤杂志202042(10):781-797.
[6]
Gradishar WJMoran MSAbraham J,et al. NCCN Guidelines® Insights:Breast Cancer,Version 4.2021[J]. J Natl Compr Canc Netw202119(5):484-493.
[7]
Tagliafico ASPiana MSchenone D,et al. 2020. Overview of radiomics in breast cancer diagnosis and prognostication[J]. Breast49:74-80.
[8]
Zheng CYu ZG. Clinical practice guidelines for pre-operative evaluation of breast cancer:Chinese Society of Breast Surgery(CSBrS)practice guidelines 2021[J]. Chin Med J(Engl)2021134(18):2147-2149.
[9]
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南2021[M]. 北京:人民卫生出版社,2021.
[10]
Expert Panel on Breast Imaging,Slanetz PJMoy L,et al. ACR Appropriateness Criteria(®)Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer[J]. J Am Coll Radiol201714(11S):S462-S475.
[11]
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤(CSCO)中枢神经系统转移性肿瘤诊疗指南2021[M],北京:人民卫生出版社,2021.
[12]
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志202131(10):954-1040.
[13]
Constantinidou AMartin ASharma B,et al. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer:a large retrospective study from the Royal Marsden Hospital[J]. Ann Oncol201122(2):307-314.
[14]
Eubank WBMankoff DBhattacharya M,et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer[J]. AJR Am J Roentgenol2004183(2):479-486.
[15]
向泓雨,刘倩,刘荫华. 2021版《中华医学会乳腺外科临床实践指南》重点内容解读[J]. 中国实用外科杂志202141(11):1257-1261.
[16]
Tarantino PGandini SNicolò E,et al. 2022. Evolution of low HER2 expression between early and advanced-stage breast cancer[J]. Eur J Cancer163:35-43.
[17]
Modi SJacot WYamashita T,et al. 2022. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer[J]. N Engl J Med387:9-20.
[18]
Robson METung NConte P,et al. OlympiAD final overall survival and tolerability results:Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer[J]. Ann Oncol201930(4):558-566.
[19]
Jr Geyer CEGarber JEGelber RD,et al. 2022. Overall survival in the OlympiA phase Ⅲ trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk,early breast cancer[J]. Ann Oncol,2022,33(12):1250-1268.
[20]
向泓雨,刘荫华. 2022年《中华医学会乳腺外科临床实践指南》更新解读[J]. 中国肿瘤外科杂志202214(03):219-223.
[21]
Price DDMcgrath PARafii A,et al. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain[J]. Pain198317(1):45-56.
[22]
lane WOthomas SMblitzblau RC,et al. Surgical Resection of the Primary Tumor in Women With De Novo Stage Ⅳ Breast Cancer:Contemporary Practice Patterns and Survival Analysis[J]. Ann Surg2019269(3):537-544.
[23]
Si YYuan PHu N,et al. Primary Tumor Surgery for Patients with De Novo Stage Ⅳ Breast Cancer can Decrease Local Symptoms and Improve Quality of Life[J]. Ann Surg Oncol202027(4):1025-1033.
[24]
Soran AOzmen VOzbas S,et al. Primary Surgery with Systemic Therapy in Patients with de Novo Stage Ⅳ Breast Cancer:10-year Follow-up;Protocol MF07-01 Randomized Clinical Trial[J]. J Am Coll Surg2021233(6):742-751.e5.
[25]
King TALyman JPGonen M,et al. Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage Ⅳ Breast Cancer:TBCRC 013[J]. J Clin Oncol201634(20):2359-2365.
[26]
Khan SAZhao FGoldstein LJ,et al. Early Local Therapy for the Primary Site in De Novo Stage Ⅳ Breast Cancer:Results of a Randomized Clinical Trial(EA2108)[J]. J Clin Oncol202240(9):978-987.
[27]
Rao RFeng LKuerer HM,et al. Timing of surgical intervention for the intact primary in stage Ⅳ breast cancer patients[J]. Ann Surg Oncol200815(6):1696-1702.
[28]
Ruiterkamp JErnst MFvan de Poll-Franse LV,et al. Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis[J]. Eur J Surg Oncol200935(11):1146-1151.
[29]
Pathy NBVerkooijen HMTaib NA,et al. Impact of breast surgery on survival in women presenting with metastatic breast cancer[J]. Br J Surg201198(11):1566-1572.
[30]
Rapiti EVerkooijen HMVlastos G,et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis[J]. J Clin Oncol200624(18):2743-2749.
[31]
Cardoso FPaluch-Shimon SSenkus E,et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer(ABC 5)[J]. Ann Oncol202031(12):1623-1649.
[32]
Friedel GPastorino UGinsberg RJ,et al. Results of lung metastasectomy from breast cancer:prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases[J]. Eur J Cardiothorac Surg200222(3):335-344.
[33]
Abbott DEBrouquet AMittendorf EA,et al. Resection of liver metastases from breast cancer:estrogen receptor status and response to chemotherapy before metastasectomy define outcome[J]. Surgery2012151(5):710-716.
[34]
Bilani NYaghi MMain O,et al. Metastasectomy versus radiation of secondary sites in stage Ⅳ breast cancer:Analysis from a national cancer registry[J]. Breast202160:185-191.
[35]
Fan JChen DDu H,et al. Prognostic factors for resection of isolated pulmonary metastases in breast cancer patients:a systematic review and meta-analysis[J]. J Thorac Dis20157(8):1441-1451.
[36]
Feng YHe XGZhou CM,et al. Comparison of hepatic resection and systemic treatment of breast cancer liver metastases:A propensity score matching study[J]. Am J Surg2020220(4):945-951.
[37]
Ercolani GZanello MSerenari M,et al. Ten-Year Survival after Liver Resection for Breast Metastases:A Single-Center Experience[J]. Dig Surg201835(4):372-380.
[38]
Magnoni FColleoni MMattar D,et al. Contralateral Axillary Lymph Node Metastases from Breast Carcinoma:Is it Time to Review TNM Cancer Staging?[J]. Ann Surg Oncol202027(11):4488-4499.
[39]
Ai XWang MLi J,et al. Supraclavicular lymph node dissection with radiotherapy versus radiotherapy alone for operable breast cancer with synchronous ipsilateral supraclavicular lymph node metastases:a real-world cohort study[J]. Gland Surg20209(2):329-341.
[40]
张薇,齐晓敏,陈翱翔,等. 锁上淋巴结清扫在初诊伴锁上淋巴结转移乳腺癌患者治疗中的作用[J]. 中华肿瘤杂志201739(05):374-379.
[41]
Gnerlich JJeffe DBDeshpande AD,et al. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer:analysis of the 1988-2003 SEER data[J]. Ann Surg Oncol200714(8):2187-2194.
[42]
Khan SAStewart AKMorrow M. Does aggressive local therapy improve survival in metastatic breast cancer?[J]. Surgery2002132(4):620-626;discussion 6-7.
[43]
Lian CLGuo LYZhang L,et al. Aggressive Local Treatment Improves Survival in Stage Ⅳ Breast Cancer With Synchronous Metastasis[J]. Front Oncol202010:522580.
[44]
Pons-Tostivint EKirova YLusque A,et al. Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis[J]. Radiother Oncol2020145:109-116.
[45]
Viani GAGouveia AGLouie AV,et al. Stereotactic body radiotherapy to treat breast cancer oligometastases:A systematic review with meta-analysis[J]. Radiother Oncol2021164:245-250.
[46]
向泓雨,刘荫华. 制定高质量临床实践指南推动中国乳腺外科诊治规范化进程[J/CD]. 中华普外科手术学杂志(电子版),202216(02):119-122.
[47]
张毅,万安第. 开展中国乳腺外科腔镜手术多中心研究的思考[J/CD]. 中华普外科手术学杂志(电子版),202216(02):127-131.
[1] 阚艳敏, 王东, 丁建民, 经翔. 住院医师规范化培训教学活动指南在超声医学教学中的应用[J]. 中华医学超声杂志(电子版), 2023, 20(05): 537-541.
[2] 中华医学会骨科学分会关节外科学组, 广东省医学会骨质疏松和骨矿盐疾病分会, 广东省佛山市顺德区第三人民医院. 中国髋部脆性骨折术后抗骨质疏松药物临床干预指南(2023年版)[J]. 中华关节外科杂志(电子版), 2023, 17(06): 751-764.
[3] 李辉, 吴奇, 张子琦, 张晗, 王仿, 许鹏. 日间全膝关节置换术早期疗效及标准化流程探索[J]. 中华关节外科杂志(电子版), 2023, 17(06): 889-892.
[4] 陈严城, 忻慰, 李世傲, 钱嘉天, 钱齐荣, 牛大伟, 赵天磊, 符培亮. 髋膝关节置换日间手术和住院手术的倾向性匹配研究[J]. 中华关节外科杂志(电子版), 2023, 17(04): 462-469.
[5] 张银银, 李颖, 李启活, 郭海威, 田瀚, 钟业霖. 髋腰综合征诊断与手术治疗的研究进展[J]. 中华关节外科杂志(电子版), 2023, 17(04): 549-553.
[6] 王玲燕, 邹磊, 洪亮, 宋三兵, 付润, 熊胜男, 宋晓春. 心脏外科术后患者并发低三碘甲状腺原氨酸综合征的影响因素分析[J]. 中华危重症医学杂志(电子版), 2023, 16(05): 399-402.
[7] 刘林峰, 王增涛, 王云鹏, 钟硕, 郝丽文, 仇申强, 陈超. 足底内侧皮瓣联合甲骨皮瓣在手指V度缺损再造中的临床应用[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 480-484.
[8] 张浩, 张万福, 韩飞, 佟琳, 王运帷, 李少辉, 陈阳, 曹鹏, 官浩. 游离组织瓣治疗无吻合血管或需困难吻合血管创面的临床进展[J]. 中华损伤与修复杂志(电子版), 2023, 18(05): 442-446.
[9] 李双喜, 胡宗凯, 赵静, 黄洁. 肝血管瘤治疗指征及治疗策略[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 504-510.
[10] 田驹, 孙伯洋, 杨荣华, 赵向前. 术中意外发现肝外胆管绒毛管状腺瘤的外科处理经验:附两例报道并文献复习[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 567-571.
[11] 张天献, 吕云福, 郑进方. 胆总管结石微创治疗进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 585-588.
[12] 廖承煜, 江斌华, 黄龙, 王丹凤, 田毅峰, 陈实. 腹腔镜下肝左叶肝内胆管细胞癌根治术优化三步法的应用价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 395-400.
[13] 李晓东, 魏云. 冠状切口额下入路治疗前颅窝巨大脑膜瘤[J]. 中华神经创伤外科电子杂志, 2023, 09(05): 318-319.
[14] 程相阵. 腹茧症9例诊治分析并文献复习[J]. 中华临床医师杂志(电子版), 2023, 17(9): 968-971.
[15] 秦建军, 郭旭峰, 胡杨, 李向楠, 李卓毅, 林江波, 梅新宇, 唐鹏, 王长春, 王枫, 王洪琰, 尹俊, 袁勇, 赵晋波, 李志刚, 李印. 日本2022版食管癌诊治指南在中国的接受度——中国红杉树专家调研[J]. 中华胸部外科电子杂志, 2023, 10(04): 195-199.
阅读次数
全文


摘要